ISDA

Entry Detail

PDB ID:

3DBS

Keywords:

TRANSFERASE

Title:

Structure of PI3K gamma in complex with GDC0941

Biological Source:

Source Organism:

Homo sapiens

PDB Version:

Deposition Date:

2008-06-02

Release Date:

2008-06-17

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.80 Å

R-Value Free:

0.26

R-Value Work:

0.21

R-Value Observed:

0.22

Space Group:

C 1 2 1

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Description:Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma isoform
Chain IDs:A
Chain Length:960
Number of Molecules:1
Biological Source:Homo sapiens

UniProt ID:P48736 Pfam ID:PF00794, PF00792, PF00613, PF00454 EC:2.7.1.137

Ligand Molecules

GD9

Primary Citation

The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer

Folkes, A.J, Ahmadi, K, Alderton, W.K, Alix, S, Baker, S.J, Box, G, Chuckowree, I.S, Clarke, P.A, Depledge, P, Eccles, S.A, Friedman, L.S, Hayes, A, Hancox, T.C, Kugendradas, A, Lensun, L, Moore, P, Olivero, A.G, Pang, J, Patel, S, Pergl-Wilson, G.H, Raynaud, F.I, Robson, A, Saghir, N, Salphati, L, Sohal, S, Ultsch, M.H, Valenti, M, Wallweber, H.J.A, Wan, N.C, Wiesmann, C, Workman, P, Zhyvoloup, A, Zvelebil, M.J, Shuttleworth, S.J.Show

J.Med.Chem. 51 5522 5532 (2008)

PMID: 18754654 DOI: 10.1021/jm800295d

Abstact

Phosphatidylinositol-3-kinase (PI3K) is an important target in cancer due to the deregulation of the PI3K/ Akt signaling pathway in a wide variety of tumors. A series of thieno[3,2-d]pyrimidine derivatives were prepared and evaluated as inhibitors of PI3 kinase p110alpha. The synthesis, biological activity, and further profiling of these compounds are described. This work resulted in the discovery of 17, GDC-0941, which is a potent, selective, orally bioavailable inhibitor of PI3K and is currently being evaluated in human clinical trials for the treatment of cancer.

Legend

Protein

Chemical

Disease

Primary Citation of related structures